MDI and DPI Drug Products
...The guidance sets forth information that should be provided to ensure continuing drug.....manufacturing, processing, packaging, controls, stability testing, or labeling operations.....stability test storage conditions. Additional studies should be performed to characterize..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=100)

HUMAN DRUG CGMP NOTES, June 1997
...Because in large containers dosage units near the closure may have different stability.....Welcome to another edition of Human Drug CGMP Notes, our periodic memo on CGMP for human.....05 also establishes that in some cases, it may not be necessary for a manufacturer to test..
http://www.fda.gov/cder/hdn/cnotes67.htm (score=109)

Guidanc for Industry: Container and Closure Integrity Testing in Lieu of...
...testing of drugs, and provides a general indication of the information on product.....test with an appropriate container and closure integrity test in the stability protocol.....microbial barrier, and, hence, the sterility of a drug product throughout its shelf..life..
http://www.fda.gov/cber/gdlns/contain.pdf (score=80)

stability guidance -draft
...Significant change for a drug product at the accelerated stability condition and the.....In general, moderate and excellent stability mean little or no change in product test results for.....The stability of the drug product after reconstituting or diluting according to labeling..
http://www.fda.gov/cder/guidance/1707dft.pdf (score=78)

/a//content.14388
...Mixing, granulating, milling, molding, of components, drug product containers, formulating.....The accuracy, sensitivity, specificity, test the product for the presence of the.....whether they use terminal sterilization, three initial batches in the stability.. Sampling..
http://www.fda.gov/cder/dmpq/fr5396.pdf (score=67)

Human Drug Notes
...65 require that equipment used in processing of a drug product be suitable for its intended use.....A practice observed during some inspections of finished drug manufacturers is the transcription of test results from the supplier's.....In the latter case, until appropriate stability data is generated, the expiration date..
http://www.fda.gov/cder/hdn/hdn1295.htm (score=62)

þÿ
...18 The applicant and/or drug product manufacturer must establish the reliability of the.....process test and the drug substance test, the acceptance criterion for the in-process test.....should explain the scientific reasons why a stability indicating procedure is not viable..
http://www.fda.gov/cder/guidance/3969DFT.pdf (score=56)

þÿ
...18 The applicant and/or drug product manufacturer must establish the reliability of the.....process test and the drug substance test, the acceptance criterion for the in-process test.....should explain the scientific reasons why a stability indicating procedure is not viable..
http://www.fda.gov/OHRMS/DOCKETS/98fr/2003d-0571-gdl0001.pdf (score=55)

Guidance for Industry: Human Somatic Cell Therapy and Gene Therapy
...See"Guideline on validation of the limulus amebocyte lysate test as an end-product.....Murphy, HFM-17, Center for Biologics Evaluation and Research, Food and Drug Administration.....developed and product stability should be studied to assure product integrity. In addition..
http://www.fda.gov/cber/gdlns/somgene.pdf (score=48)

PTC in Manufacture and Testing of Monoclonal Antibody Products for Human Use
...Validation of the LAL Test as an End-Product Endotoxin Test for Human and Animal.....are used, master vector seed stocks should be generated, and the genetic stability of the.....entity or is produced by a novel process, and when drug development plans are unusually..
http://www.fda.gov/cber/gdlns/ptc_mab.pdf (score=46)

...The conditions under which product stability is evaluated and the positive and negative controls.....See also "Guidelines on Validation of the LAL Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs.....Sponsors should study a number of separate product lots during drug development to demonstrate that a safe and..
http://www.fda.gov/cber/gdlns/ptc_mab.txt (score=46)

PET Drug Products … Current Good Manufacturing Practice (CGMP)
...ensure that each batch of PET drug product meets its established acceptance criteria, 1201.....stability parameters include radiochemical identity and purity, appearance, pH, stabilizer.....of false-positive results arises in the sampling and transfer of the test aliquot from the..
http://www.fda.gov/cder/guidance/4259dft.pdf (score=46)

Packaging
...It should provide an adequate seal, be compatible with the drug product, and not be a source of.....This information should include the proposed market package for the product and the relevant stability and.....A further test to supplement the mouse subchronic systemic test is the procedure for eye..
http://www.fda.gov/cder/guidance/package.htm (score=44)

PET Drug Products - Current Good Manufacturing Practice (CGMP)
...Appropriate parameters should be evaluated to establish and document the stability of a PET drug product under.....The reliability of the supplier's test results can be established by conducting.....Stability testing of the PET drug product should be performed at the highest radioactive concentration, and the whole batch..
http://www.fda.gov/cder/guidance/4259dft.htm (score=44)

þÿ
...No clinically significant drug-drug interactions between itraconazole, theophylline, warfarin.....microorganism is not fully susceptible to alternative, clinically feasible drugs, the test.....The potential for pharmacokinetic drug interactions between moxifloxacin and itraconazole..
http://www.fda.gov/cder/foi/label/2002/21085s6s7lbl.pdf (score=43)

þÿ
...No clinically significant drug-drug interactions between theophylline, warfarin, digoxin.....microorganism is not fully susceptible to alternative, clinically feasible drugs, the test.....The color does not affect, nor is it indicative of, product stability. The inactive.. ingredients..
http://www.fda.gov/cder/foi/label/2002/21085s12lbl.pdf (score=43)

Guidance for Industry
...ensuring that the drug product provided to the patient has the appropriate identity, strength.....and approved lot, we recommend that the manufacturer test the combined product and approve.....provided that they meet appropriate standards or specifications as demonstrated by..
http://www.fda.gov/OHRMS/DOCKETS/98fr/03d-0165-gdl0001.pdf (score=43)

Validation of Chromatographic Methods
...Solution stability of the drug substance or drug product after preparation..according to the test method should be evaluated.....with the regulatory impurities method relating to release and stability of..both drug substance and drug product.Detection limit is.....The objective of a test method is to generate reliable and accurate data regardless of..
http://www.fda.gov/cder/guidance/cmc3.pdf (score=42)

Q1B Photostability Testing of New Drug Substances and Products
...The extent of drug product testing should be established by assessing whether or not acceptable.....The ICH Harmonized Tripartite Guideline on Stability Testing of New Drug Substances and.....Care should be taken to ensure that the physical characteristics of the samples under test..
http://www.fda.gov/cder/guidance/1318.htm (score=39)

HUMAN DRUG CGMP NOTES December 1998
...84, Testing and approval or rejection of components, drug product containers, and closures.....As of May, 1998, TOC is the official organic impurities test for USP pharmaceutical.....84, Testing and approval or rejection of components, drug product containers, and closures..
http://www.fda.gov/cder/hdn/cnotesd8.htm (score=38)

Las Vegas Injury Lawyer